Dapagliflozin in STEMI
Condition: ST Elevation Myocardial Infarction · Myocardial Infarction · Sponsor: Ottawa Heart Institute Research Corporation
About this study
The goal of this clinical trial is to assess the safety and efficacy of SGLT2i in limiting infarct size in patients with STEMI referred for PPCI. Eligible STEMI patients enrolled into the trial will be randomized to a SGLT2i or placebo. Cardiovascular Magnetic Resonance (CMR) imaging will be used to determine the infarct size.
This description comes directly from the study's public registry record.
Talk to the study team
Poppy MacPhee, BScN · 6136967000 · pmacphee@ottawaheart.ca
Tanya Abarbanel · 613-696-7000 · tabarbanel@ottawaheart.ca
Always discuss trial participation with your own doctor first.
Locations (1)
| University of Ottawa Heart Institute | Ottawa, Ontario, Canada | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06174753